Home » Sorafenib Gets Mixed Results in KRAS-Positive NSCLC
Sorafenib Gets Mixed Results in KRAS-Positive NSCLC
More than half of patients with non-small cell lung cancer and KRAS mutations had partial responses or stable disease when treated with the targeted agent sorafenib, a Dutch study showed.
MedPage Today
MedPage Today
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May